LNA gapmers targeting mutant TNPO3 partially restore molecular and cellular defects in LGMDD2 muscle cells

Technical Summary: LNA Gapmers Targeting Mutant TNPO3 in LGMDD2 Muscle Cells

Problem Statement
Limb-girdle muscular dystrophy type D2 (LGMDD2) is a rare autosomal dominant myopathy caused by a single nucleotide deletion (c.2771delA) in the TNPO3 gene. This mutation results in a frameshift and the production of a mutant Transportin-3 (TNPO3) protein with an abnormal C-terminal extension (p.924Cext15). The disease mechanism is driven by the expression of this pathogenic mutant protein, which acts via a toxic gain-of-function or dominant-interfering mechanism. TNPO3 is a nuclear import receptor essential for the nuclear import of serine/arginine-rich (SR) proteins, critical for RNA splicing regulation. The mutant protein disrupts cellular homeostasis, leading to altered protein turnover, dysregulated autophagy-lysosome pathways (evidenced by p62 accumulation and LC3 alterations), and impaired myogenic differentiation. Currently, treatments for LGMDD2 are exclusively palliative, necessitating the development of therapies that target the primary genetic cause. While genome editing has shown that correcting the mutation restores phenotypes, it remains unclear whether more modest, pharmacologically achievable reductions of the mutant transcript are sufficient to ameliorate disease-associated defects.

Methodology
The study utilized patient-derived muscle cells (myotubes) from individuals with LGMDD2. The researchers designed and evaluated four LNA-modified antisense gapmers (Gapmer1–4) targeting the mutant TNPO3 transcript. These oligonucleotides feature a 5–10–5 architecture (flanking LNA nucleotides with a central DNA gap) to recruit endogenous RNase H for transcript degradation.

The experimental workflow included:

1. Cytotoxicity Screening: An MTS assay was performed to determine sub-cytotoxic working concentrations (selected as 100 nM) to ensure observed effects were not due to cell death.
2. Efficacy Assessment: Quantitative RT-PCR (TaqMan) and Western blotting were used to measure TNPO3 mRNA and protein levels, respectively, distinguishing between total, wild-type (WT), and mutant alleles.
3. Allele Selectivity: Allele-specific probes were employed to calculate a selectivity factor (SF_g), determining the extent to which each gapmer reduced the mutant transcript relative to the WT transcript.
4. Phenotypic Analysis: The study assessed disease-relevant cellular markers, including:
   • Proteostasis/Autophagy: LysoTracker staining for lysosomal vesicles, and Western blot analysis of p62/SQSTM1 and LC3-II/LC3-I ratios.
   • Myogenic Differentiation: Immunofluorescence for desmin, quantification of myotube diameter, and fusion index calculations.
5. Integrative Analysis: A semi-quantitative framework was used to compare multidimensional molecular and phenotypic changes across treatment groups.

Key Results

• Transcript and Protein Reduction: All four gapmers significantly reduced TNPO3 mRNA levels (ranging from 47% to 61% reduction) and total TNPO3 protein levels in LGMDD2 cells compared to untreated controls.
• Allele Selectivity: While all gapmers reduced the mutant transcript, their selectivity varied. Gapmer2 and Gapmer3 demonstrated the highest allele selectivity, preferentially reducing the mutant allele while largely preserving the WT allele. Gapmer1 showed limited selectivity, reducing both alleles similarly.
• Restoration of Proteostasis: Treatment with gapmers partially normalized autophagy and lysosome-related markers. Specifically, the treatment reduced the elevated LysoTracker signal (indicating lysosomal accumulation) and modulated the LC3-II/LC3-I ratio and p62 levels, bringing them closer to control values.
• Rescue of Myogenic Differentiation: LGMDD2 cells exhibited impaired myogenic differentiation characterized by reduced myotube diameter and a lower fusion index. Gapmer treatment partially restored both parameters, shifting the phenotype toward that of healthy control cells.
• Correlation of Effects: The study observed that phenotypic rescue (improvement in differentiation and proteostasis) occurred even with incomplete allele selectivity. The degree of functional recovery did not strictly correlate linearly with the magnitude of mutant allele reduction across all candidates, suggesting threshold effects or contributions from total TNPO3 reduction.

Significance and Claims
The paper establishes a proof-of-concept for using LNA-modified gapmers as an RNA-targeting therapeutic strategy for LGMDD2. The primary claim is that partial reduction of the pathogenic mutant TNPO3 protein is sufficient to ameliorate key molecular and cellular defects in LGMDD2 muscle cells, even in the absence of complete allele selectivity.

The authors emphasize that while total TNPO3 suppression must be balanced to avoid disrupting essential nuclear transport functions, the observed partial reduction of the mutant allele successfully normalized disease-associated phenotypes, including autophagy dysregulation and defective myogenic differentiation. The study supports the feasibility of gapmer-mediated modulation as a promising approach for dominant neuromuscular disorders driven by toxic gain-of-function mechanisms. However, the authors note that further research is required to assess long-term specificity, off-target effects, dosage optimization, and in vivo efficacy before clinical translation.